Radhakrishnan, Sabarinath V.
Luetkens, Tim http://orcid.org/0000-0002-7085-9027
Scherer, Sandra D.
Davis, Patricia
Vander Mause, Erica R.
Olson, Michael L. http://orcid.org/0000-0002-1566-2029
Yousef, Sara
Panse, Jens
Abdiche, Yasmina
Li, K. David
Miles, Rodney R.
Matsui, William
Welm, Alana L.
Atanackovic, Djordje
Funding for this research was provided by:
American Association for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA042014)
National Comprehensive Cancer Network (NCCN) Young Investigator Award
U.S. Department of Defense (W81XWH-12-1-0077)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30CA042014)
Article History
Received: 17 July 2019
Accepted: 21 January 2020
First Online: 7 February 2020
Competing interests
: D.A., T.L. and S.V.R. are inventors on PCT application US2017/42840 “Antibodies and CAR T Cells for the Treatment of Multiple Myeloma” describing the therapeutic use of CD229 CAR T cells for the treatment of multiple myeloma. The other authors declare no competing interests.